Recently, ApoE−/− mice on HFD (with compositions ranging from 37–60% of kcal as fat, with a carbohydrate content of 38–44% and supplementation of 0.02–1.5% cholesterol and of 0.5% cholate, administered from seven to 24 weeks [77,78,79,80,81,82,83,84,85,86,87,88,89,90,91]) have been utilized as NAFLD/NASH models to investigate the pathogenesis and progression of this disease, as well as potential therapeutic treatments. Here, APOE is linked to metabolic dysfunction-associated steatohepatitis.